In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Camptosar Patient Genotype Testing For Neutropenia Risk Marker Advised

  • News

Executive Summary

Patient genotype is a predictive factor for neutropenic adverse events in patients receiving Pfizer's oncologic Camptosar, FDA's Clinical Pharmacology Subcommittee of the Pharmaceutical Science Advisory Committee agreed Nov. 3

You may also be interested in...



Medco Personalized Medicine Research Shows “Real World” Promise – Frueh

Medco's research can advance the cause of personalized medicine by proving its benefits in a "real world" setting, according to Felix Frueh, the firm's new VP of research and development for personalized medicine

Medco Personalized Medicine Research Shows “Real World” Promise – Frueh

Medco's research can advance the cause of personalized medicine by proving its benefits in a "real world" setting, according to Felix Frueh, the firm's new VP of research and development for personalized medicine

Biomarker Working Group To Explore Development Of Guidance

An FDA working group will be formed by year-end to consider the development of a guidance on biomarkers

Table

View full table

Tags:
Latest Headlines

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

South Korea Sees Pharma Leadership Transition

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

See All
UsernamePublicRestriction

Register

PS044957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By